Strados FeNO
Fractional Exhaled Nitric Oxide
NObreath® — Point-of-Care FeNO Measurement
A rapid, reliable biomarker for Type 2 airway inflammation. FeNO measurement provides objective evidence of eosinophilic inflammation to support patient stratification, endpoint assessment, and treatment monitoring in respiratory trials.
Design a Study
Capabilities
Key Features
Rapid Results
Results available within seconds at the point of care. No lab processing or sample shipping required.
Patient Stratification
Identify and enrich for Type 2 high patients at screening to improve trial population selection.
Treatment Monitoring
Track inflammatory response over time to demonstrate pharmacodynamic effect of anti-inflammatory therapies.
Validated Biomarker
Established correlation with eosinophilic airway inflammation. Recognized by ATS/ERS clinical guidelines.
Simple Technique
Non-invasive breath test with guided flow rate control for reproducible measurements across sites.
Portable Device
Compact, portable design for easy deployment across global trial sites with minimal site training.
Clinical Value
FeNO as a clinical trial endpoint
FeNO provides a non-invasive, reproducible measure of airway inflammation that complements pulmonary function and patient-reported outcomes.
Enrich study populations
Use FeNO at screening to select patients with Type 2 inflammation, improving response rates and signal detection.
Pharmacodynamic endpoint
FeNO change from baseline provides objective evidence of anti-inflammatory mechanism of action.
Complement spirometry
FeNO captures inflammatory status that spirometry alone cannot assess, adding dimension to your endpoint strategy.
Reduce sample size requirements
Better patient selection through FeNO-based enrichment can reduce the number of subjects needed for adequate power.
Strados Intelligence Advantage
Reliable supply for your clinical trial
NObreath® offers consistent global availability, portable design, and minimal site training — solving the supply constraints that often limit Niox deployment in clinical trials. Strados partnerships ensure dedicated supply chains and white-glove logistics support for uninterrupted enrollment.
Part of the Strados Endpoint Suite
FeNO + the full endpoint suite
Combine FeNO with spirometry, cough monitoring, and eCOA to build the most complete picture of respiratory disease status and treatment response.
Explore the Full Endpoint SuiteReady to design your respiratory study?
Tell us about your program and we'll help you design the right respiratory endpoint strategy.
Design a Study
